Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 5.31%
As of Thursday, July 30, Oruka Therapeutics, Inc.’s ORKA share price has surged by 5.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Commentary & Analysis
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 8.04%
As of Friday, July 17, Oruka Therapeutics, Inc.’s ORKA share price has surged by 8.04%, which has investors questioning if this is right time to sell.Michael Rose
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 6.42%
As of Tuesday, July 07, Oruka Therapeutics, Inc.’s ORKA share price has surged by 6.42%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 7.88%
As of Thursday, July 02, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 7.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 10.24%
As of Thursday, July 02, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 10.24%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,902.1 | $251.9 | 70% |
|
| Shares Out (Mil) | 55.2 | 50.8 | 50% |
|
| Institutional Ownership | 97.1% | 92.0% | 73% |
|
| Float (Mil) | 51.1 | 40.5 | 48% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 1,039 | 447 | 71% |
|
| Price Change (52-week) |
612.8% | 54.2% | 100% |
|
| Growth | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (9.8%) | na |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.500) | ($2.039) | ($2.492) | |
| Month Ago EPS | ($0.500) | ($2.037) | ($2.462) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.528) | ($2.157) | ($2.581) | |
| Year/Year Chg | 4.6% | 10.3% | 90.4% | |
| Financials | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($116) | ($43) | 10% |
|
| EPS (TTM) | ($1.923) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($91) | ($30) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($34) | $3 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 18% |
|
| Enterprise Value (Q1) (Mil) | $3,244 | $182 | 56% |
|
| Valuation | ORKA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.15 | 2.60 | 90% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (26.4%) | (49.7%) | 18% |
|
| ROE | (27.5%) | (55.4%) | 21% |
|
| Liabilities to Assets | 3.5% | 30.3% | 1% |
|
| F-Score | 3 | 3 | 19% |
|
Oruka Therapeutics, Inc. did not pass any screens on 7/30/2026.
